Evidence map›Paper›PMID 30066203›Full record

ArticleVirchows Archiv : an international journal of pathology2018

Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.

Minna Nortunen, Heikki Huhta, Olli Helminen, Seppo Parkkila, Joonas H Kauppila, Tuomo J Karttunen, Juha Saarnio

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.Digestive diseases and sciences · 2022
    Article
  2. Article
  3. Article
  4. Carbonic Anhydrases II and IX in Non-ampullary Duodenal Adenomas and Adenocarcinoma.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Minna NortunenCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland. minna.nortunen@gmail.com.ORCID http://orcid.org/0000-0003-0928-150X
Heikki HuhtaCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland.
Olli HelminenCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland.
Seppo ParkkilaFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Joonas H KauppilaCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland.
Tuomo J KarttunenCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland.
Juha SaarnioCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, 90014, Oulu, Finland.
Oulu University Hospital · FIKarolinska University Hospital · SETampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of our retrospective study was to investigate the expression and clinical significance of the cancer-associated carbonic anhydrases (CAs) II, IX, and XII in Barrett's esophagus and esophageal adenocarcinoma (EAC). We evaluated 101 archival specimens from patients with EAC as well as seven and 26 samples from patients with high-and low-grade dysplasia, respectively. In addition, normal esophageal squamous epithelium, gastric, and intestinal metaplasia were analyzed when present. The expression patterns of isozymes were detected by immunohistochemistry. CAII and CIX expression levels were lower in the squamous epithelium than in the columnar cells while CAXII showed an opposite pattern and was present mainly in squamous epithelium. Expression patterns in benign, dysplastic, or malignant esophageal columnar lesions were not significantly different. The assessment of clinicopathological associations showed that CAII was significantly downregulated in metastatic disease (p = 0.026). CAIX showed no association with prognosis, although there appeared to be an association (p = 0.056) between high expression and nodal spread. In conclusion, CAII, CAIX, and CAXII do not serve as biomarkers for different phases in the development of EAC.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBarrett EsophagusBiomarkersCarbonic Anhydrase IICarbonic Anhydrase IXCarbonic AnhydrasesDown-RegulationEsophageal NeoplasmsFemaleFollow-Up StudiesHumansImmunohistochemistryAntigens, NeoplasmBiomarkersCA9 protein, humanCarbonic Anhydrase IICarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase XIIBarrett’s esophagusCAIICAIXCAXIIEsophageal adenocarcinoma

Identifiers

PMID30066203
OpenAlexW2886740131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.